Literature DB >> 23988873

Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.

K E Caudle1, C F Thorn, T E Klein, J J Swen, H L McLeod, R B Diasio, M Schwab.   

Abstract

The fluoropyrimidines are the mainstay chemotherapeutic agents for the treatment of many types of cancers. Detoxifying metabolism of fluoropyrimidines requires dihydropyrimidine dehydrogenase (DPD, encoded by the DPYD gene), and reduced or absent activity of this enzyme can result in severe, and sometimes fatal, toxicity. We summarize evidence from the published literature supporting this association and provide dosing recommendations for fluoropyrimidines based on DPYD genotype (updates at http://www.pharmgkb.org).

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23988873      PMCID： PMC3831181          DOI： 10.1038/clpt.2013.172

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  39 in total

1.  Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.

Authors:  X Wei; H L McLeod; J McMurrough; F J Gonzalez; P Fernandez-Salguero
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

2.  Comprehensive analysis of pyrimidine metabolism in 450 children with unspecific neurological symptoms using high-pressure liquid chromatography-electrospray ionization tandem mass spectrometry.

Authors:  C Schmidt; U Hofmann; D Kohlmüller; T Mürdter; U M Zanger; M Schwab; G F Hoffmann
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

3.  5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency.

Authors:  M Boisdron-Celle; G Remaud; S Traore; A L Poirier; L Gamelin; A Morel; E Gamelin
Journal:  Cancer Lett       Date:  2006-10-24       Impact factor: 8.679

4.  Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity.

Authors:  A B Van Kuilenburg; P Vreken; L V Beex; R Meinsma; H Van Lenthe; R A De Abreu; A H van Gennip
Journal:  Eur J Cancer       Date:  1997-11       Impact factor: 9.162

5.  Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W.

Authors:  P Vreken; A B Van Kuilenburg; R Meinsma; A H van Gennip
Journal:  Hum Genet       Date:  1997-12       Impact factor: 4.132

6.  Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance.

Authors:  Alain Morel; Michele Boisdron-Celle; Luc Fey; Patrick Soulie; Marie Claire Craipeau; Sori Traore; Erick Gamelin
Journal:  Mol Cancer Ther       Date:  2006-11       Impact factor: 6.261

7.  Characterization of the human dihydropyrimidine dehydrogenase gene.

Authors:  X Wei; G Elizondo; A Sapone; H L McLeod; H Raunio; P Fernandez-Salguero; F J Gonzalez
Journal:  Genomics       Date:  1998-08-01       Impact factor: 5.736

8.  Population study of dihydropyrimidine dehydrogenase in cancer patients.

Authors:  M C Etienne; J L Lagrange; O Dassonville; R Fleming; A Thyss; N Renée; M Schneider; F Demard; G Milano
Journal:  J Clin Oncol       Date:  1994-11       Impact factor: 44.544

9.  Mutational spectrum of dihydropyrimidine dehydrogenase gene (DPYD) in the Tunisian population.

Authors:  Radhia Ben Fredj; Eva Gross; Lotfi Chouchen; Fatma B'Chir; Slim Ben Ahmed; Steffi Neubauer; Marion Kiechle; Saâd Saguem
Journal:  C R Biol       Date:  2007-09-07       Impact factor: 1.583

10.  Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity.

Authors:  G Milano; M C Etienne; V Pierrefite; M Barberi-Heyob; R Deporte-Fety; N Renée
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640
View more
  107 in total

1.  Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil.

Authors:  Saranya Kodali; Venu Bathini; Paul Rava; Eswar Tipirneni
Journal:  J Gastrointest Cancer       Date:  2017-03

2.  Fluoropyrimidine-Associated Cardiotoxicity: A Retrospective Case-Control Study.

Authors:  Inbar Raber; Sarah Warack; Jaya Kanduri; Abby Pribish; Anuradha Godishala; Arielle Abovich; Anna Orbite; Sujithraj Dommaraju; Morgan Frazer; Mary Linton Peters; Aarti Asnani
Journal:  Oncologist       Date:  2019-12-16

3.  Scanning the human genome and the horizon: the potential and pitfalls of pharmacogenetics and stratified medicine.

Authors:  Barbara A Jennings; Tom Shakespeare; Yoon K Loke
Journal:  Br J Gen Pract       Date:  2015-06       Impact factor: 5.386

4.  Lethal 5-fluorouracil toxicity in a colorectal patient with severe dihydropyrimidine dehydrogenase (DPD) deficiency.

Authors:  Carole Dhelens; Agnès Bonadona; Fabienne Thomas; Claire Chapuis; Leila Potton; Sabrina Marsili; Pierrick Bedouch; Carole Schwebel
Journal:  Int J Colorectal Dis       Date:  2015-03-22       Impact factor: 2.571

5.  Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil.

Authors:  Catc Lunenburg; J J Swen; H-J Guchelaar; H Gelderblom
Journal:  J Gastrointest Cancer       Date:  2017-03

Review 6.  Pharmacogenomics in dermatology: tools for understanding gene-drug associations.

Authors:  Roxana Daneshjou; Rachel Huddart; Teri E Klein; Russ B Altman
Journal:  Semin Cutan Med Surg       Date:  2019-03-01

7.  Histone H3K27 Trimethylation Modulates 5-Fluorouracil Resistance by Inhibiting PU.1 Binding to the DPYD Promoter.

Authors:  Rentian Wu; Qian Nie; Erin E Tapper; Calvin R Jerde; Garrett S Dunlap; Shikshya Shrestha; Tarig A Elraiyah; Steven M Offer; Robert B Diasio
Journal:  Cancer Res       Date:  2016-08-30       Impact factor: 12.701

Review 8.  Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.

Authors:  Keith T Schmidt; Cindy H Chau; Douglas K Price; William D Figg
Journal:  J Clin Pharmacol       Date:  2016-06-17       Impact factor: 3.126

9.  First-line treatment with hepatic arterial infusion plus capecitabine vs capecitabine alone for elderly patients with unresectable colorectal liver metastases.

Authors:  Xiaodong Li; Liangrong Shi; Jun Wu; Mei Ji; Jiemin Zhao; Weiguang Qiang; Wenge Ding; Jingting Jiang; Qicheng Lu; Changping Wu
Journal:  Cancer Biol Ther       Date:  2016       Impact factor: 4.742

10.  Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance).

Authors:  Adam M Lee; Qian Shi; Steven R Alberts; Daniel J Sargent; Frank A Sinicrope; Jeffrey L Berenberg; Axel Grothey; Blase Polite; Emily Chan; Sharlene Gill; Morton S Kahlenberg; Suresh G Nair; Anthony F Shields; Richard M Goldberg; Robert B Diasio
Journal:  Pharmacogenet Genomics       Date:  2016-03       Impact factor: 2.089
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.